Advances in Adjuvant Therapy For Cutaneous Melanoma

The goal of this review is to summarize the exciting new advances in adjuvant therapy for stage III and stage IV (surgically resected) melanoma

Systemic adjuvant therapy for high-risk cutaneous melanoma - PMC

Altogether, these studies support significant potential benefits for neoadjuvant immunotherapy and targeted therapy in locoregionally advanced operable melanoma ...

Adjuvant and neoadjuvant therapy for cutaneous melanoma

- Initial surgery, followed by adjuvant therapy · - BRAF wild-type tumors · Adjuvant nivolumab · Adjuvant pembrolizumab · Adjuvant therapies not ...

Questions remain on optimal adjuvant therapy in advanced melanoma

Real-world studies report greater benefits with targeted therapy than immunotherapy in patients with BRAFV600 mutations, but adjuvant treatment ...

Treatment of cutaneous melanoma: current approaches and future ...

Surgical resection with or without lymph node sampling is the standard of care for primary cutaneous melanoma. Adjuvant therapy decisions may be informed by ...

Current State of Adjuvant Therapy for Melanoma: Less Is More, or ...

Despite the dramatic improvements in survival for patients with advanced melanoma treated with immune checkpoint inhibitors, approximately 50% ...

Melanoma Adjuvant Therapy: Reducing the Risk of Recurrence

Adjuvant therapy is an additional treatment given after the primary treatment for a disease. In melanoma, adjuvant therapy is sometimes used after surgery ...

Understanding How New Neoadjuvant and Adjuvant Therapy ...

Patients with locally advanced (stage III) melanoma currently have 5-year recurrence-free survival rates of only 50% despite curative surgery ...

Advances in Melanoma and Other Skin Cancers Research - NCI

Treatment for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma · cemiplimab (Libtayo) for some people with metastatic or locally ...

Adjuvant immunotherapy for melanoma patients - ESMO Open

The immunotherapeutic treatment landscape for patients with high-risk melanoma has increased in complexity at a rapid pace. · Neoadjuvant ...

Adjuvant and neoadjuvant therapy for cutaneous melanoma

Checkpoint inhibition immunotherapy and targeted therapies are important advances in the treatment of patients with cutaneous melanoma, in ...

Adjuvant Therapy for High-Risk Stage II Melanoma - MDPI

Melanoma is the fifth most common cancer in the United States and accounts for the majority of all skin cancer-related deaths, making it the most lethal ...

Adjuvant Treatments of Adult Melanoma: A Systematic Review and ...

Nivolumab is the optimum adjuvant treatment for unresectable advanced or metastatic melanoma with a good risk-benefit profile.

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in ...

Neoadjuvant Pembrolizumab for Advanced Melanoma ... Patients with stage III or IV melanoma who have undergone surgical excision remain at high ...

Good News on Adjuvant Therapy for Advanced Cutaneous Melanoma

The estimated recurrence-free survival rate (RFSR) at 3 years was 58% in the CTT group compared with 39% in the placebo group (HR, 0.47; 95% CI, 0.39-0.58; P<.

Adjuvant therapies for melanoma - DermNet

Adjuvant therapy is defined as a treatment given after the initial therapy. In the case of cutaneous melanoma, adjuvant therapy is a form of treatment ...

Exploring Advancements and Challenges in Adjuvant Melanoma ...

Melanoma of the skin is a common type of cancer that primarily affects younger patients. In Stage III melanoma, which does not involve distant ...

The treatment of advanced melanoma: Current approaches and new ...

Studies have suggested that metastatic (MM) may show less benefit from immunotherapy treatments compared to metastatic cutaneous melanoma. MM generally exhibits ...

Advances in Adjuvant Therapy for the Treatment of High-risk ...

Detection of circulating tumor cells (CTC) by molecular approaches may also be a promising prognostic biomarker in melanoma patients. In a ...

Adjuvant Therapy for Cutaneous Melanoma

Immunotherapy (in the form of ipilimumab, nivolumab, and pembrolizumab) in the adjuvant setting for node-positive melanoma has been shown to improve recurrence- ...